2-(4-thiazol-4-yl-phenoxy)-ethylamine | 416859-86-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-thiazol-4-yl-phenoxy)-ethylamine
• 英文别名: 2-[4-(1,3-Thiazol-4-yl)phenoxy]ethanamine
• CAS: 416859-86-4
• 化学式: C₁₁H₁₂N₂OS
• 分子量: 220.295
• InChiKey: NESOHPRJIIVVKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  76.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-thiazol-4-yl-phenoxy)-ethylamine 、 2-chloro-5-[(2R)-2-oxiranyl]pyridine 以 乙醇 为溶剂， 反应 16.0h， 生成 (1R)-1-(6-chloropyridin-3-yl)-2-[2-[4-(1,3-thiazol-4-yl)phenoxy]ethylamino]ethanol
  参考文献：
  名称：

  Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

  摘要：

  A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human beta(3)-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the beta(3)-AR, functional selectivity against beta(1)- and beta(2)-ARs, and favorable pharmacokinetic profiles in vivo. Compound 17 increased oxygen consumption in rats, a measure of energy expenditure, with an EDO20% of 2 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.072
• 作为产物：
  描述：

  在 甲烷磺酸 、 苯甲醚 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 2-(4-thiazol-4-yl-phenoxy)-ethylamine
  参考文献：
  名称：

  Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

  摘要：

  A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human beta(3)-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the beta(3)-AR, functional selectivity against beta(1)- and beta(2)-ARs, and favorable pharmacokinetic profiles in vivo. Compound 17 increased oxygen consumption in rats, a measure of energy expenditure, with an EDO20% of 2 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.072

文献信息

• Bita3 adrenergic receptor agonists and uses thereof
  申请人：——

  公开号：US20020052392A1

  公开（公告）日：2002-05-02

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式（I）的β3肾上腺素受体激动剂，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y的定义如本文所述。本发明还提供了在制备结构式（I）化合物中有用的中间体，结构式（I）化合物的组合，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐与抗肥胖药物的组合；包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐的药物组合；或包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，以及抗肥胖药物的药物组合的药物组合；以及治疗β3肾上腺素受体介导的疾病、症状或障碍的方法，该方法包括向哺乳动物施用结构式（I）化合物、其立体异构体或前药的有效量，或其药物组合；或者结构式（I）化合物、其药用盐、立体异构体或前药，以及抗肥胖药物的组合，或其药物组合。
• Beta3 adrenergic receptor agonists and uses thereof
  申请人：Pfizer Inc.

  公开号：US20030203913A1

  公开（公告）日：2003-10-30

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供结构式（I）的&bgr;3肾上腺素受体激动剂，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y如所述。本发明还提供在制备式（I）化合物中有用的中间体，以及式（I）化合物的组合物，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐与抗肥胖剂的组合物；以及包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，或包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐和抗肥胖剂的药物组合物。本发明还提供治疗哺乳动物&bgr;3肾上腺素受体介导的疾病、病况或障碍的方法，该方法包括向哺乳动物施用有效量的式（I）化合物、其立体异构体或前药，或其药物组合物；或者是式（I）化合物、其药学上可接受的盐、立体异构体或前药的组合物和抗肥胖剂，或其药物组合物的组合物。
• ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1326861A1

  公开（公告）日：2003-07-16
• US6566377B2
  申请人：——

  公开号：US6566377B2

  公开（公告）日：2003-05-20
• US6706743B2
  申请人：——

  公开号：US6706743B2

  公开（公告）日：2004-03-16